ORAMED PHARMACEUTICALS INC (ORMP)
Health Care · Biopharmaceutical / oral protein delivery · NASDAQ
Oramed is a clinical-stage pharmaceutical company developing oral insulin delivery technology while actively investing in healthcare companies to diversify capital allocation.
What ORAMED PHARMACEUTICALS INC does
Oramed Pharmaceuticals is a research and development-focused pharmaceutical company engaged in developing innovative oral delivery solutions for therapeutic proteins, particularly insulin. The company has developed a proprietary dosage form designed to withstand the gastrointestinal tract and safely deliver active proteins without chemical modification. In addition to its core pharmaceutical operations, Oramed strategically allocates capital to investments in healthcare and life sciences companies that complement its long-term business objectives and technology focus.
Themes: oral insulin / diabetes treatment, drug delivery platforms, healthcare strategic investments
Fundamentals
- Price$4.81 as of 2026-08-21 close
- Market cap$200M as of 2026-08-21
- 1-year return+133.5% 2025-08-21 close $2.06 → 2026-08-21 close $4.81
- P/E1.66 as of 2026-08-25
- Net margin-838.4% as of 2026-08-25
- ROE+55.1% as of 2026-08-25
- Debt / equity0.00 as of 2026-08-25
- Revenue growth (YoY)-30.9% as of 2026-08-25
- Revenue CAGR (3y)-7.3% SEC XBRL
- Beta1.27 as of 2026-08-25
- Last reported earnings2025-11-17 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
Dividend: at least 1 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How ORMP compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-25
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-25
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-25
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-25
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ORAMED PHARMACEUTICALS INC looks technically
ORAMED PHARMACEUTICALS INC (ORMP) is trading 34.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 218 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-06-30, pushing above its recent trading range.
Trend
8
| Distance from the 200-day | it is trading 34.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +34.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.26 | $4.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.58 | $3.58 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 4.16. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 218 trading days ago — a "golden cross", a bullish long-term signal | 218 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 27.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 68.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($4.16 to $4.94) — its "stochastic" reading is 83 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 83.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.19 | $5.19 |
|---|---|---|
| From the 52-week high | it is 7.3% below its 52-week high (its highest price of the past year) | -7.3% |
| Above the 52-week low | it is 135.2% above its 52-week low (its lowest price of the past year) | +135.2% |
| Below the 52-week high | it is 7.3% below its highest point of the past year | 7.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-06-30, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 41 trading days ago | 41 sessions |
| All-time high | its highest closing price on record is $31.73 (set on 2014-01-13) | $31.73 |
| Given back of the 52-week move | over the past year its closes ranged ($2.06 to $5.00), and it has given back only a small part of its rise from last year’s low — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.09 to $3.18. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.5% |
| From the all-time high | it is 84.8% below its all-time high | -84.8% |
| Nearest price level | it is trading 12.9% above a support level at $4.19 — a price it turned at twice since 2026-04-28, most recently on 2026-08-11. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -12.9% |
| All-time low | its lowest closing price on record is $1.68 (set on 2023-11-02) | $1.68 |
| Above the all-time low | it is 187.0% above its all-time low | +187.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 58th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2036 between its high and its low — about 4.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2036 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.88 and $4.88 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.88 – $4.38 – $4.88 |
| Typical daily range (% of price) | its price moves about 4.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.2% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (34.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Open gap | it gapped 2.8% above the previous close 48 sessions ago and has not traded back through the level it left behind at 3.64 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.8% |
| Gap filled | a 2.2% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 17.3 percentage points (the stock gained 19.7% while the market gained 2.3%) | +17.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.7 percentage points (the stock gained 9.8% while the market gained 3.1%) | +6.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 38.3 percentage points (the stock gained 49.4% while the market gained 11.1%) | +38.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 113.0 percentage points (the stock gained 133.5% while the market gained 20.5%) | +113.0% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.4% of the share price, which is taken to mean a barrier that gives way easily. | +9.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.02 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +19.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.57 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +5.2% |
Price levels it has turned at before
ORMP last closed at $4.81 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.19 | Support | 12.9% below the last close | turned there twice · 2026-04-28 to 2026-08-11 |
| $3.94 | Support | 18.1% below the last close | turned there four times · 2026-04-17 to 2026-07-31 |
| $3.22 | Support | 33.1% below the last close | turned there twice · 2025-12-12 to 2025-12-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $4.16.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market · Printed a doji candle · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$6.25 range $6.25 – $6.25
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["High reliance on clinical trial success for lead oral insulin candidate; failure to achieve efficacy or safety endpoints would significantly impact the company's valuation.","Significant historical net losses and dependence on capital-intensive development processes.","Business model includes exposure to volatility in strategic investments and financial instruments."]
What changed in the latest 10-Q
AI-assisted comparison of ORMP's 10-Q filed 2026-05-19 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-19) describes Oramed as 'a strategic operator of medical technology businesses' that acquires controlling interests and actively manages portfolio companies, rather than as a pharmaceutical company engaged in R&D of oral protein delivery technology
- Newer filing adds April 19, 2026 extension of Scilex Tranche A Note maturity to June 15, 2026 with specific payment schedule and option to satisfy through Datavault shares
- Newer filing adds May 8, 2026 receipt of 7,000,000 Datavault shares from Scilex
- Newer filing adds details on Pelthos Therapeutics transactions: July 1, 2025 purchase of 150,000 shares for $1,500,000, sale of 6,577 shares for $173,000, and post-March 31, 2026 sales of 143,423 shares for $3,451,000 resulting in zero position as of May 19, 2026
- Newer filing adds Nano Dimension Ltd. investment activity: 11,838,730 shares purchased for $20,759,000 as of March 31, 2026; 1,269,987 shares sold for $2,606,000; post-March 31, 2026 purchases of 1,336,565 shares for $2,288; option-related sales of 1,325,000 shares for $2,650; holding 10,579,708 shares as of May 19, 2026
- Newer filing adds Hapisga Project loan information: March 2025 loan agreements up to $27,650; March 31, 2026 extension extending maturity to April 2, 2028 with principal converted to NIS 100,000,000 and Tova Chochma removed as party
- Newer filing adds April 15, 2026 investment of $2,500,000 in junior participation interest in 83 Wythe LLC construction loan with 9% preferred annual return and maturity October 15, 2028
- Newer filing adds May 13, 2026 investment of $3,000,000 in participation interest in Warren at Bay LLC mortgage loan with 8% coupon and 4% promote, maturing May 13, 2029
- Removed:
- Older filing (2025-11-13) describes company as 'a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins'
- Older filing describes oral dosage form development for insulin or other proteins designed to withstand gastrointestinal tract environment
- Older filing discusses Phase 2 and Phase 3 clinical data and identified high-responder subgroups with potential for over 1% HbA1c reduction
- Older filing discusses intent to initiate 60-patient US-based clinical trial to validate oral insulin formulation in high-responder populations
- Older filing provides detailed Scilex transaction history from September 21, 2023 including Tranche A Note terms, exercise of penny warrants in October 2024, and sale of Transferred Warrants for $300,000
- Older filing describes January 21, 2025 Tranche A Note amendment extending maturity to December 31, 2025 with 92,858 shares of Scilex received as consideration
- Older filing describes October 7, 2024 Tranche B Note transaction with $50,000,000 principal and warrants, with Oramed purchasing 50% ($25,000,000)
- Older filing describes October 8, 2024 Royalty Purchase Agreement for 4% royalties on ZTLido and SP-103 net sales for 10 years
- Reworded:
- Reference to 'Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 26, 2026' in newer filing replaces older reference to 'Annual Report' without specific filing date
- Newer filing references 'condensed consolidated financial statements' in opening paragraph while older filing uses same language, maintaining consistency but with updated filing context
- Notes:
- The two filings represent substantially different business narratives: the newer filing emphasizes portfolio company operations and investment activities, while the older filing emphasized pharmaceutical R&D. This reflects either a strategic pivot or a change in how the company characterizes its operations.
- The older filing text appears truncated at 'ZTLido Rest of th' suggesting the comparison source may be incomplete for the older filing.
- Dates in newer filing (filed 2026-05-19) are presented as future dates relative to typical document review timing, but are treated as stated in the filing.
Risk Factors
- Added:
- Annual Report on Form 10-K reference changed to fiscal year ended December 31, 2025 filed March 26, 2026 (newer filing)
- Balance sheet date changed to March 31, 2026 (newer filing)
- New line item 'Investment in Lifeward' for $22,492 thousand as of March 31, 2026 (newer filing)
- Convertible note of $4,636 thousand removed from current assets between periods (comparison of December 31, 2025 to March 31, 2026)
- Dividend Payable increased to $303 thousand (current) and $198 thousand (long-term) as of March 31, 2026 (newer filing)
- Deferred revenues of $2,000 thousand removed from long-term liabilities between periods (comparison shows it in older December 31, 2025 but not in March 31, 2026)
- Three months ended March 31 period for comprehensive income statement (newer filing shows Q1 2026 and Q1 2025)
- Gain on sale of IP of $5,821 thousand reported in cash flows (newer filing)
- Other income, net increased to $8,250 thousand in Q1 2026 (newer filing)
- Removed:
- Annual Report on Form 10-K reference to fiscal year ended December 31, 2024 filed March 27, 2025, amended July 16, 2025 (older filing)
- Balance sheet date of September 30, 2025 (older filing)
- Nine months ended September 30 period presentations in comprehensive income and cash flow statements (older filing)
- Interest expenses line item in comprehensive income statement (present in older filing, absent in newer filing for the comparison period)
- Reworded:
- Reference dates in risk factor disclosure updated from December 31, 2024 annual report to December 31, 2025 annual report
- Reference to amendment date removed: older filing mentions 'amended on July 16, 2025' while newer filing does not include amendment reference
- Balance sheet presentation: older filing titled 'Balance Sheets' while newer filing specifies 'Balance sheets as of March 31, 2026 and December 31, 2025'
- Equity section header changed from 'EQUITY ATTRIBUTABLE TO COMPANY'S STOCKHOLDERS' in older filing to 'EQUITY' in newer filing for the March 31, 2026 balance sheet
- Notes:
- Comparison involves different reporting periods: Q3 2025 (older filing dated 2025-11-13) versus Q1 2026 (newer filing dated 2026-05-19), making period-to-period financial comparisons not directly comparable
- The older filing presents nine-month and three-month data while newer filing presents only three-month data, reflecting different interim reporting structures
- Cash flow statement in newer filing appears truncated in the source text provided, limiting full comparison of investing and financing activities
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($942175) — 2 selling insiders
- Last 180 days0 buys · 2 sells ($942175) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-01. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ORMP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ORMP from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding ORMP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 338,721
- Reported value $1,151,651
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ORMP had 835,493 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ORMP had 2.01% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.69 days to cover at the same settlement.
- Reported short interest (shares) 835,493
- Short interest (% of shares outstanding) 2.01%
- Prior settlement (shares) 765,356
- Reported change 9.16%
- Days to cover (reported) 5.69
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Sanofi (SNY)
- MannKind (MNKD)
- Provention Bio (PRVB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ORMP vs…
ORMP ranks in…
Frequently asked questions
What does ORAMED PHARMACEUTICALS INC (ORMP) do?
Oramed Pharmaceuticals is a research and development-focused pharmaceutical company engaged in developing innovative oral delivery solutions for therapeutic proteins, particularly insulin. The company has developed a proprietary dosage form designed to withstand the gastrointestinal tract and safely deliver active proteins without chemical modification.
What sector is ORAMED PHARMACEUTICALS INC (ORMP) in?
ORAMED PHARMACEUTICALS INC (ORMP) is classified in the Health Care sector. Its industry is Biopharmaceutical / oral protein delivery. It trades on NASDAQ.
Who are ORAMED PHARMACEUTICALS INC's (ORMP) competitors?
Notable peers of ORAMED PHARMACEUTICALS INC (ORMP) include Novo Nordisk, Eli Lilly, Sanofi, MannKind and Provention Bio. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ORMP?
Yes — we hold 1 matched STOCK Act disclosure for ORMP from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ORAMED PHARMACEUTICALS INC (ORMP) overbought or oversold right now?
ORAMED PHARMACEUTICALS INC (ORMP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ORMP come from?
Fundamentals and prices come from market data, as of 2026-08-25; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.